Product Details
Actemra 400 mg/20 mL (Tocilizumab) Injection In Pakistan
Actemra 400mg/20ml Injection contains tocilizumab, a monoclonal antibody and interleukin-6 (IL-6) receptor antagonist. Tocilizumab works by blocking IL-6 signaling, which plays an important role in inflammatory and immune responses.
Actemra is prescribed for selected inflammatory and autoimmune conditions, including rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis. It is also approved for certain patients with cytokine release syndrome and COVID-19 under specified clinical circumstances.
The 400mg/20ml presentation is a single-dose vial containing 20mg/ml of tocilizumab for intravenous infusion after appropriate dilution.
Benefits
- Contains tocilizumab 400mg/20ml.
- Targets the IL-6 receptor pathway involved in inflammation.
- Used for several approved inflammatory and immune-mediated conditions.
- May help reduce inflammation and disease activity when appropriately prescribed.
- Supplied as a concentrated 20mg/ml intravenous formulation.
- Suitable for administration by trained healthcare professionals.
- Can be incorporated into an individualized treatment plan under specialist supervision.
Specifications
| Specification | Details |
|---|---|
| Brand | Actemra |
| Active Ingredient | Tocilizumab |
| Strength | 400mg/20ml |
| Concentration | 20mg/ml |
| Dosage Form | Injection / Infusion Solution |
| Route | Intravenous infusion |
| Presentation | Single-dose vial |
| Volume | 20ml |
| Drug Class | IL-6 receptor antagonist |
| Therapeutic Category | Immunomodulator / Anti-inflammatory biologic |
| Manufacturer | Genentech / Roche |
| Prescription Status | Prescription medicine |
The official product information identifies the 400mg/20ml vial as a single-dose intravenous formulation requiring dilution before infusion.
How To Use
Actemra 400mg/20ml must be administered by a qualified healthcare professional. The intravenous formulation is diluted using an appropriate infusion solution and administered as an IV drip, generally over approximately 1 hour. It must not be administered as an IV bolus or push.
The dose depends on the medical condition, patient's weight, age, laboratory results and response to treatment. Therefore, do not determine or change the dose yourself.
Before and during treatment, healthcare professionals may monitor blood counts, liver function and other laboratory parameters. Patients should also be evaluated for infections, including tuberculosis when appropriate.
Why Choose Actemra?
Actemra is an established tocilizumab-based biologic therapy that specifically targets the IL-6 receptor pathway. This targeted mechanism makes it an important treatment option for appropriately selected patients with certain inflammatory and immune-mediated diseases.
